Results 11 to 20 of about 1,232,763 (338)
A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022 Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song +11 more
wiley +1 more source
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Biomedicines, 2021 Despite advances in pharmacotherapy, intervention devices and techniques, residual cardiovascular risks still cause a large burden on public health. Whilst most guidelines encourage achieving target levels of specific lipids and lipoproteins to reduce ...
Chih-Kuo Lee +5 more
doaj +1 more source
HDL and plaque regression in a multiphase model of early atherosclerosis [PDF]
, 2023 Atherosclerotic plaques are accumulations of cholesterol-engorged macrophages in the artery wall. Plaque growth is initiated and sustained by the deposition of low density lipoproteins (LDL) in the artery wall. High density lipoproteins (HDL) counterbalance the effects of LDL by accepting cholesterol from macrophages and removing it from the plaque. In
arxiv +1 more source
Primary genetic disorders affecting high density lipoprotein (HDL)
Drugs in Context, 2018 There is extensive evidence demonstrating that there is a clear inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) concentration and cardiovascular disease (CVD).
Constantine E Kosmas +5 more
doaj +1 more source
Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington’s Disease
Cells, 2023 Alterations in lipid composition and disturbed lipoprotein metabolism are involved in the pathomechanism of Huntington’s disease (HD). Here, we measured 112 lipoprotein subfractions and components in the plasma of 20 normal controls, 24 symptomatic ...
Kuo-Hsuan Chang +5 more
doaj +1 more source
Heart India, 2019 Background: Patients are treated with statins for the control of cholesterol; but statins control only low-density lipoprotein (LDL) and not non-high-density lipoprotein (non-HDL). Also, LDL is not a good coronary risk predictor.
A K Badrinath +5 more
doaj +1 more source
Dysfunctional high-density lipoprotein [PDF]
Current Opinion in Endocrinology, Diabetes & Obesity, 2009 To address the progress of the investigation on dysfunctional high-density lipoprotein (HDL).HDL is generally considered to be an independent protective factor against cardiovascular disease. However, emerging evidence indicates that HDL can be modified under certain circumstances and lose its protective effect or even become atherogenic.
Xiang-An Li, Hong Feng
openaire +3 more sources
Cardiovascular Diabetology, 2023 Background High-density lipoprotein cholesterol’s (HDL-C) long-held status as a cardiovascular disease (CVD) preventative has been called into question. Most of the evidence, however, focused on either the risk of death from CVD, or on single time point ...
Hye Jun Kim +5 more
doaj +1 more source
High-Density Lipoprotein and Heart Failure
Reviews in Cardiovascular Medicine, 2023 The protective effect of high-density lipoprotein (HDL) on atherosclerosis is well known, and its mechanisms of action has been extensively studied. However, the impact of HDL on heart failure and its mechanisms are still controversial or unknown.
Liyun Xing +4 more
doaj +1 more source
High-density lipoprotein cholesterol: How High
Indian Journal of Endocrinology and Metabolism, 2012 The high-density lipoprotein cholesterol (HDL-C) is considered anti-atherogenic good cholesterol. It is involved in reverse transport of lipids. Epidemiological studies have found inverse relationship of HDL-C and coronary heart disease (CHD) risk.
G Rajagopal, V Suresh, Alok Sachan
doaj +1 more source